Silence Therapeutics plc (LON:SLN – Get Free Report)’s stock price passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 535 ($6.95) and traded as low as GBX 512 ($6.65). Silence Therapeutics shares last traded at GBX 535 ($6.95), with a volume of 913,528 shares.
Silence Therapeutics Stock Down 0.9 %
The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.36 and a current ratio of 4.52. The firm has a market capitalization of £480.35 million and a PE ratio of -11.01. The company has a fifty day moving average price of GBX 535 and a 200-day moving average price of GBX 535.
Silence Therapeutics Company Profile
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
See Also
- Five stocks we like better than Silence Therapeutics
- What is the Dow Jones Industrial Average (DJIA)?
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- What Investors Need to Know About Upcoming IPOs
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
